Local and systemic inflammatory mediator release in patients with acute and chronic posttraumatic osteomyelitis

Journal of Trauma - Injury, Infection and Critical Care

Volumn 40, Issue 3, 1996, Pages 372-378

  Klosterhalfen, B ^a   Peters, K M ^a   Tons C ^b   Hauptmann, S ^a   Klein, C L ^c   Kirkpatrick, C J ^c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Interleukin 1 ; Interleukin 6; Interleukin 8; Leukotriene B4; Posttraumatic osteomyelitis; Prostaglandin I2; Thromboxane A2; Tumor necrosis factor alpha

Indexed keywords

ANTIBIOTIC AGENT; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; PROSTACYCLIN; PROSTAGLANDIN F1 ALPHA; THROMBOXANE A2; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INJURY; LIQUID SCINTILLATION COUNTING; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; NEUTROPHIL; OSTEOMYELITIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0029917279     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-199603000-00008     Document Type: Article

References (43)

1. Probst J: Häufigkeit der Osteomyelitis nach Osteosynthesen. Chirurg 48:6, 1977
2. Maatz R: Zur Infekthäufigkeit nach gedeckter und offener Nagelung geschlossener Frakturen. Aktuel Traumatol 13:175, 1983
3. Burn C: Häufigkeit und Prophylaxe der prosttraumatischen Osteitis. In Burn C, Neugebauer R (eds: Bern, Huber-Verlag, Infektion von Knochen und Gelenken. 1989, pp 8-16
4. Roesgen M, Hierholzer G, Hax PM: Post-traumatic osteomyelitis: Pathophysiology and management. Arch Orthop Trauma Surg 108:1, 1989
5. Norden CW: Lessons learned from animal models of osteomyelitis. Rev Infect Dis 10:103, 1988
6. Dekel S, Francis MJO: The treatment of osteomyelitis of the tibia with sodium salicylate: An experimental study in rabbits. J Bone Joint Surg Br 63:178, 1981
7. Jacob E, Arendt DM, Brook I, et al: Enzyme-linked immunosorbent assay for detection of antibodies to Staphylococcus aureus cell walls in experimental osteomyelitis. J Clin Microbiol 22:547, 1985
8. Norden CW, Shinners E, Niederreitter K: Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis 153:956, 1986
9. Norden CW: Experimental osteomyelitis. IV. Therapeutic trials with rifampicin alone and in combination with gentamicin, sisomicin, and cephalotin. J Infect Dis 132:493, 1975
10. Norden CW: Experimental osteomyelitis. V. Therapeutic trials with oxacillin and sisomicin alone and in combination. J Infect Dis 137:155, 1978
11. Norden CW, Shaffer M: Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampicin. J Infect Dis 147:352, 1983
12. Norden CW, Shinners E: Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. J Infect Dis 151:291, 1985
13. Norden CW, Niederreiter K: Ofloxacin therapy of experimental osteomyelitis caused by Pseudomonas aeruginosa. J Infect Dis 155:823, 1987
14. Norden CW: Experimental chronic staphylococcal osteomyelitis in rabbits: Treatment with rifampin alone and in combination with other antimicrobial agents. Rev Infect Dis 5(Suppl 3):S491, 1983
15. Waldvogel FA, Vasey H: Osteomyelitis: The past decade. N Engl J Med 303:360, 1980
16. Waldvogel FA, Medoff G, Swartz MN: Osteomyelitis: A review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med 282:198, 1970
17. Capitanio MA, Kirkpatrick JA: Early roentgen observations in acute osteomyelitis. AJR Am J Roentgenol 108:488, 1970
18. Härle A: Infection management in total replacement. Arch Orthop Trauma Surg 108:63, 1989
19. Peters KM, Koberg K, Kehren H, et al: Die PMN-Elastase in der Diagnostik und Verlaufskontrollevon Knochen- und Gelenkinfektionen. Unfallchirurg 94:376, 1991
20. Klosterhalfen B, Hörstmann-Jungemann K, Vogel P, et al: The course of various inflammatory mediators during recurrent endotoxemia. Biochem Pharmacol 43:2103, 1992
21. Klosterhalfen B, Hörstmann-Jungemann K, Vogel P, et al: Hemodynamic variables and plasma levels of PGI2, TxA2 and IL-6 in a porcine model of recurrent endotoxemia. Circ Shock 35:237, 1991
22. Lefer AM: Significance of lipid mediators in shock states. Circ Shock 27:3, 1989
23. Flohe S, Heinrich PC, Schneider J, et al: Time course of IL-6 and TNF alpha release during endotoxin-induced endotoxin tolerance in rats. Biochem Pharmacol 41:1607, 1991
24. Dinarello CA: Biology of interleukin 1. FASEB J 2:108, 1988
25. Haak CE, De Groot ER, Felt-Bersma JR, et al: Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704, 1989
26. Cannon JG, Tompkins RG, Gelfand JA, et al: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79, 1990
27. Ramsay G, Newman PM, McCartney AC, et al: Endotoxemia in multiple organ failure due to sepsis. Prog Clin Biol Res 272:237, 1988
28. Canalis E, McCarthy T, Centrella M: Growth factors and the regulation of bone remodeling. J Clin Invest 81:277, 1988
29. Rifas L, Cheng SL, Shen V, et al: Monokines produced by macrophages stimulate the growth of osteoblasts. Connect Tissue Res 23:163, 1989
30. Gillespie WJ, Allerdyce RA: Mechanisms of bone degradation in infection: A review of recurrent hypotheses. Orthopedics 13:407, 1990
31. Gowen M, Wood DD, Ihrie EJ, et al: An interleukin-1 like factor stimulates bone resorption in vitro. Nature 306:378, 1983
32. Stashenko P, Obernesser MS, Dewhirst FE: Effect of immune cytokines on bone. Immunol Invest 18:239, 1989
33. Sistermann R, Mölienhoff G, Walz M, et al: Eine zelluläre quantitative Immundefizienz bei der chronisch posttraumatischen Osteomyelitis. Unfallchirurg 95:254, 1992
34. Schlüter B, Bergmann U, Josten C, et al: Impairment of specific host defense mechanisms in patients with chronic posttraumatic osteomyelitis. J Trauma 31:68, 1991
35. Peters KM, Klosterhalfen B, Zwadlo-Klarwasser G, et al: Lymphozytendefekte bei der chronischen Osteomyelitis - eine prospektive Studie. Unfallchirurg 96:29, 1993
36. Peters KM, Zwadlo-Klarwasser G, Koberg K, et al: Verminderung von Makrophagensubpopulationen bei der posttraumatischen Osteomyelitis. Z Orthop Ihre Grenzgeb 131:37, 1993
37. Rissing JP, Buxton TB, Weinstein RS, et al: Model of experimental chronic osteomyelitis in rats. Infect Immun 47:581, 1985
38. Rissing JP, Buxton TB, Fisher J, et al: Arachidonic acid facilitates experimental chronic osteomyelitis in rats. Infect Immun 49:141, 1985
39. 2 in experimental staphylococcal osteomyelitis. J Infect Dis 154:627, 1986
40. Baron R, Vignery A, Horowitz M: Lymphocytes, macrophages and the regulation of bone remodeling. Bone Miner Res 2:175, 1984
41. Canalis E, McCarthy T, Centrella M: The regulation of bone formation by local growth factors. Bone Miner Res 6:27, 1989
42. Geiger T, Anders T, Klapproth J, et al: Induction of rat acute-phase proteins by interleukin-6 in vivo. Eur J Immunol 18:717, 1988
43. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 265:621, 1990